|   From the Trenches

New Directions In Alzheimer’s Disease Research And Development

Disappointing results in Alzheimer’s clinical trials seem to be announced on an almost monthly, and sometimes weekly basis:

  • Merck’s verubecestat
  • vTv’s azeliragon
  • Lilly’s solanezumab

Unfortunately, these are just a few examples…there are many more.

This blog was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC.

Read more.